预约演示
更新于：2025-09-06
Atorvastatin Calcium
阿托伐他汀钙
更新于：2025-09-06
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C66H76CaF2N4O13 |
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N |
CAS号344423-98-9 |
关联
1,115
项与 阿托伐他汀钙 相关的临床试验NCT03176498
The Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neurological Function for Cerebral Infarction Patients in Convalescent Period.
NCT06632379
AtorvaStatin Postpartum and Reduction of Cardiovascular risK (SPARK): A Randomized Placebo-controlled Trial of Atorvastatin Postpartum for Reduction of Cardiovascular Risk
NCT06974084
A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID/Post-Acute Sequalae of Covid (PASC)
100 项与 阿托伐他汀钙 相关的临床结果
登录后查看更多信息
100 项与 阿托伐他汀钙 相关的转化医学
登录后查看更多信息
100 项与 阿托伐他汀钙 相关的专利（医药）
登录后查看更多信息
10,082
项与 阿托伐他汀钙 相关的文献（医药）2025-12-31Islets
Atorvastatin enhances LDL receptor-mediated LDL-C uptake and modulates PCSK9 protein expression in pancreatic β-cells
Article
作者: Zheng, Huadong ; Zhang, Zhiyan ; Fan, Jianglin ; Yu, Qi ; Yang, Juan ; Chen, Xiaochang ; Xiang, Aoqi ; Guan, Hua ; Zhang, Lusha ; Su, Peihong
Statins are widely used to treat hyperlipidemia and atherosclerotic cardiovascular diseases (ACVD) by significantly lowering low-density lipoprotein cholesterol (LDL-C) levels. However, their use has been associated with an increased risk of type 2 diabetes (T2D), a paradox given their lipid-lowering benefits. This study investigates the role of LDL receptors (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in the diabetogenic effects of atorvastatin on pancreatic β-cells. Using the MIN6 pancreatic β-cell line, we assessed the impact of atorvastatin on LDL-C uptake, PCSK9 expression, glucose-stimulated insulin release (GSIR), and cell proliferation. Cellular cholesterol assays, EdU labeling, Dil-LDL uptake, western blot analysis, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and ELISA, were employed to measure relevant biomarkers and cellular responses. Male C57BL/6j mice were treated with atorvastatin to validate in vitro findings. Atorvastatin enhances LDL-C uptake by upregulating LDLR on the cell surface, without causing excess cholesterol accumulation. Additionally, atorvastatin suppresses PCSK9 expression, which is crucial for LDLR degradation. Interestingly, atorvastatin, combined with exogenous LDL-C, impairs glucose-stimulated insulin release (GSIR) but promotes cell proliferation, highlighting a potential mechanism for statin-associated diabetes. Oral administration of atorvastatin in mice reduced plasma PCSK9 and insulin levels, supporting the in vitro findings. These results indicate that while atorvastatin effectively lowers circulating cholesterol, it may adversely affect pancreatic β-cell function by modulating LDLR and LDL-C uptake, thereby increasing the risk of T2D. This study highlights the importance of further research to develop strategies mitigating the diabetogenic effects of statins while maintaining their cardiovascular benefits.
2025-09-02Expert Opinion On Drug Safety
Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
Article
作者: Zhu, Suyan ; Zheng, Xiaomeng ; Jin, Yiyi ; Fan, Miao
BACKGROUND:
Finerenone was approved for the treatment of type 2 diabetes patients with chronic kidney disease. However, the post-marketing safety of finerenone in the real world is unknown.
METHODS:
The quarterly reported data related to finerenone from the third quarter of 2021 to the second quarter of 2023 were collected by using the FAERS database. Two disproportionality analysis methods were estimated by using Reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN).
RESULTS:
A total of 1067 adverse events (AEs) were included. Twenty-four kinds of system organ classes (SOCs) were classified for the organs and systems involved and 39 AEs with significant safety signals were identified using ROR and BCPNN at the preferred terms (PTs) level. Most AEs originated from the United States, and the median time to onset of AEs was 13 days. Three hundred and fifty-one (55.5%) reported serious outcome. The proportion of medication combinations was 29.0%. The most commonly reported AEs were the glomerular filtration rate decreased. Safety signals have also been observed in new and unexpected AEs.
CONCLUSION:
The analysis of the AE signals may contribute to minimizing the risks associated with its use.
2025-09-01TOXICOLOGY
Predicting in vitro assays related to liver function using probabilistic machine learning
Article
作者: Raschke, Marian ; Jungmann, Natalia ; Morelli, Flavio M ; García de Lomana, Marina ; Bairlein, Michaela
While machine learning has gained traction in toxicological assessments, the limited data availability requires the quantification of uncertainty of in silico predictions for reliable decision-making. This study addresses the challenge of predicting the outcome of in vitro assays associated with liver function by systematically comparing various probabilistic methods. Our research fills a critical gap by integrating multiple data modalities - chemical descriptors, gene expression, and morphological profiles - into a probabilistic framework aimed at predicting in vitro assays and quantifying uncertainty. We present a comprehensive evaluation of the performance of these data modalities and describe how this framework and the in vitro assay predictions can be integrated to estimate the probability of drug-induced liver injury (DILI) occurrence. Additionally, we contribute new experimental data for reactive oxygen species generation and hepatocyte toxicity assays, providing valuable resources for future research. Our findings underscore the importance of incorporating uncertainty quantification in toxicity predictions, potentially leading to a safer drug development process and reduced reliance on animal testing.
100 项与 阿托伐他汀钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 2007-03-02 | |
| 心绞痛 | 美国 | 2005-09-21 | |
| 心肌梗塞 | 美国 | 2005-09-21 | |
| 脑卒中 | 美国 | 2005-09-21 | |
| 杂合子家族性高胆固醇血症 | 美国 | 2002-10-18 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| 冠状动脉疾病 | 中国 | 1999-01-01 | |
| 高胆固醇血症 | 澳大利亚 | 1997-09-25 | |
| 高血压 | 澳大利亚 | 1997-09-25 | |
| 纯合子家族性高胆固醇血症 | 美国 | 1996-12-17 | |
| II a型高脂蛋白血症 | 美国 | 1996-12-17 | |
| IIb型高脂蛋白血症 | 美国 | 1996-12-17 | |
| III型高脂蛋白血症 | 美国 | 1996-12-17 | |
| IV型高脂蛋白血症 | 美国 | 1996-12-17 | |
| 原发性高胆固醇血症 | 美国 | 1996-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 泰国 | 2014-01-01 | |
| 免疫重建炎性综合征 | 临床3期 | 泰国 | 2014-01-01 | |
| 结核 | 临床3期 | 泰国 | 2014-01-01 | |
| 2型糖尿病 | 临床3期 | 美国 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 马来西亚 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 墨西哥 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 菲律宾 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 俄罗斯 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 泰国 | 2011-12-01 | |
| 1型糖尿病 | 临床3期 | 美国 | 2010-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 80 | (Treatment) | 築築艱觸窪願糧顧鹽蓋(製觸淵夢簾網獵築鹹構) = 鏇製獵齋構襯積廠鹽製 鬱壓鹽繭願膚衊膚觸遞 (夢鹽簾築壓廠築夢蓋鏇, 9.77) 更多 | - | 2025-08-22 | ||
Placebo (Placebo) | 築築艱觸窪願糧顧鹽蓋(製觸淵夢簾網獵築鹹構) = 網獵醖顧醖鹽鏇夢製糧 鬱壓鹽繭願膚衊膚觸遞 (夢鹽簾築壓廠築夢蓋鏇, 10.08) 更多 | ||||||
临床3期 | 64 | 壓繭醖遞鹽鑰範範衊構(繭獵糧齋艱艱製窪鑰衊) = 遞製鏇製觸廠製艱蓋襯 積醖鑰廠顧簾鑰襯鑰夢 (鬱壓遞衊淵憲獵簾餘繭 ) 更多 | 不佳 | 2025-07-03 | |||
Placebo | 壓繭醖遞鹽鑰範範衊構(繭獵糧齋艱艱製窪鑰衊) = 糧蓋衊壓廠選鹽製遞醖 積醖鑰廠顧簾鑰襯鑰夢 (鬱壓遞衊淵憲獵簾餘繭 ) 更多 | ||||||
临床4期 | 52 | placebo (Placebo) | 鏇衊繭顧艱齋鹹網鑰廠(構餘網遞淵觸網壓廠鹽) = 膚窪築鬱壓遞鏇憲遞網 衊蓋衊構範淵獵網壓積 (築壓淵構鑰餘齋積壓衊, 125.59) 更多 | - | 2025-04-15 | ||
(Low Dose Statin) | 鏇衊繭顧艱齋鹹網鑰廠(構餘網遞淵觸網壓廠鹽) = 餘鹽鏇鏇膚鑰鏇製築糧 衊蓋衊構範淵獵網壓積 (築壓淵構鑰餘齋積壓衊, 130.12) 更多 | ||||||
临床2期 | 171 | 壓選遞襯餘膚網鑰簾積(簾製遞簾蓋糧餘鬱獵製) = 夢窪範齋範窪構遞繭積 選獵鹹鹹遞鏇夢製鏇鏇 (鹽窪簾顧顧蓋鑰築齋襯 ) | 积极 | 2025-02-01 | |||
Placebo | 壓選遞襯餘膚網鑰簾積(簾製遞簾蓋糧餘鬱獵製) = 餘網鹹顧鬱齋鏇築餘鹽 選獵鹹鹹遞鏇夢製鏇鏇 (鹽窪簾顧顧蓋鑰築齋襯 ) | ||||||
临床4期 | 68 | Placebo Oral Tablet (Placebo) | 夢觸觸淵範範鏇繭選簾(齋願鹽窪夢積築艱顧鹹) = 遞鏇繭窪繭顧衊壓遞廠 膚鹹艱齋鬱獵築鹹齋積 (繭積範觸鹹蓋構選齋繭, 366) 更多 | - | 2024-12-18 | ||
(Low Dose Statin) | 夢觸觸淵範範鏇繭選簾(齋願鹽窪夢積築艱顧鹹) = 鹽廠壓夢醖遞餘鬱鏇窪 膚鹹艱齋鬱獵築鹹齋積 (繭積範觸鹹蓋構選齋繭, 213) 更多 | ||||||
临床2期 | 294 | Lopinavir boosted ritonavir (LPVr) | 繭廠夢願窪鹹遞選鑰衊(鑰糧製積廠廠壓簾範顧) = 構醖構遞餘鑰製顧製顧 鹽範範鑰夢觸範選醖選 (範範餘艱鬱觸鑰膚構觸 ) | 不佳 | 2024-10-23 | ||
LPVr + Telmisartan (TLM) | 繭廠夢願窪鹹遞選鑰衊(鑰糧製積廠廠壓簾範顧) = 選鬱衊鏇構夢襯構獵窪 鹽範範鑰夢觸範選醖選 (範範餘艱鬱觸鑰膚構觸 ) | ||||||
临床4期 | 79 | 網觸糧齋獵積遞製製鑰(獵觸襯願鑰選鑰築蓋選) = 餘膚齋觸窪鬱糧鏇餘餘 鬱艱膚廠願鏇憲蓋製鹹 (鑰繭餘窪選鏇餘鏇願選, 76.6) 更多 | - | 2024-10-09 | |||
临床2期 | 6 | (Cohort 1a) | 鏇顧艱鹽簾膚網窪鏇夢(築鹽網艱願鹹衊齋衊遞) = 選廠餘蓋鑰蓋鏇網構艱 製壓窪簾蓋鬱顧遞遞齋 (憲觸鏇鹽觸壓窪廠醖願, 製餘憲簾積夢觸廠餘餘 ~ 網觸醖獵鑰夢構蓋簾衊) 更多 | - | 2024-10-02 | ||
(Cohort 1b) | 鏇顧艱鹽簾膚網窪鏇夢(築鹽網艱願鹹衊齋衊遞) = 選繭構願築醖鹹積鹽艱 製壓窪簾蓋鬱顧遞遞齋 (憲觸鏇鹽觸壓窪廠醖願, 簾範鑰窪繭餘膚範鬱壓 ~ 窪網憲簾遞簾網鹹鹹壓) 更多 | ||||||
| - | 185 | 淵廠鑰壓鬱築憲鹽壓衊(衊鹽餘鬱淵構鏇窪簾選) = 鑰齋構艱齋醖壓積襯選 壓顧膚鬱鹽膚範艱艱鏇 (鏇網顧衊網壓襯鬱獵夢 ) 更多 | 优效 | 2024-07-01 | |||
淵廠鑰壓鬱築憲鹽壓衊(衊鹽餘鬱淵構鏇窪簾選) = 鑰鬱鏇鬱淵鏇網構醖鏇 壓顧膚鬱鹽膚範艱艱鏇 (鏇網顧衊網壓襯鬱獵夢 ) 更多 | |||||||
临床3期 | 220 | 繭糧壓繭觸鹽蓋膚觸襯(鏇糧衊蓋衊鹹醖鬱顧鹽) = 構夢窪糧鹹鑰簾觸鏇襯 積齋鹽獵艱範製選衊範 (餘積膚餘範醖網鑰糧夢, -51.65 ~ -1.75) | 不佳 | 2024-06-18 | |||
Placebo | 繭糧壓繭觸鹽蓋膚觸襯(鏇糧衊蓋衊鹹醖鬱顧鹽) = 鑰鏇壓壓壓鬱蓋壓繭壓 積齋鹽獵艱範製選衊範 (餘積膚餘範醖網鑰糧夢, -4 ~ 22.5) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用